Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.
2.

Neuroprotective effect of bioflavonoid quercetin in 6-hydroxydopamine-induced oxidative stress biomarkers in the rat striatum.

Haleagrahara N, Siew CJ, Mitra NK, Kumari M.

Neurosci Lett. 2011 Aug 15;500(2):139-43. doi: 10.1016/j.neulet.2011.06.021. Epub 2011 Jun 17.

PMID:
21704673
3.

Ameliorating effects of combined curcumin and desferrioxamine on 6-OHDA-induced rat mode of Parkinson's disease.

Lv H, Liu J, Wang L, Zhang H, Yu S, Li Z, Jiang F, Niu Y, Yuan J, Cui X, Wang W.

Cell Biochem Biophys. 2014 Nov;70(2):1433-8. doi: 10.1007/s12013-014-0077-3.

PMID:
24989681
6.

The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.

Datla KP, Bennett RD, Zbarsky V, Ke B, Liang YF, Higa T, Bahorun T, Aruoma OI, Dexter DT.

J Pharm Pharmacol. 2004 May;56(5):649-54.

PMID:
15142343
7.

Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy.

Silva-Adaya D, Pérez-De La Cruz V, Villeda-Hernández J, Carrillo-Mora P, González-Herrera IG, García E, Colín-Barenque L, Pedraza-Chaverrí J, Santamaría A.

Neurotoxicol Teratol. 2011 Mar-Apr;33(2):303-12. doi: 10.1016/j.ntt.2010.10.002. Epub 2010 Oct 7.

PMID:
20933078
8.

Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures.

Kääriäinen TM, Piltonen M, Ossola B, Kekki H, Lehtonen S, Nenonen T, Lecklin A, Raasmaja A, Männistö PT.

Brain Res. 2008 Apr 8;1203:149-59. doi: 10.1016/j.brainres.2008.01.089. Epub 2008 Feb 13.

PMID:
18329008
9.

Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies.

Ahmad M, Yousuf S, Khan MB, Hoda MN, Ahmad AS, Ansari MA, Ishrat T, Agrawal AK, Islam F.

Pharmacol Biochem Behav. 2006 Jan;83(1):150-60. Epub 2006 Feb 28.

PMID:
16500697
10.

Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease.

Singh S, Ahmad R, Mathur D, Sagar RK, Krishana B.

Indian J Exp Biol. 2006 Sep;44(9):699-704.

PMID:
16999024
11.

Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson's rats: neuroprotection by serotonin, GABA and bone marrow cells supplementation.

Kuruvilla KP, Nandhu MS, Paul J, Paulose CS.

J Neurol Sci. 2013 Aug 15;331(1-2):31-7. doi: 10.1016/j.jns.2013.04.020. Epub 2013 May 28.

PMID:
23726276
12.
13.

Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.

Jin F, Wu Q, Lu YF, Gong QH, Shi JS.

Eur J Pharmacol. 2008 Dec 14;600(1-3):78-82. doi: 10.1016/j.ejphar.2008.10.005. Epub 2008 Oct 10.

PMID:
18940189
14.

Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK.

Neurobiol Dis. 2006 May;22(2):421-34. Epub 2006 Feb 9.

PMID:
16480889
15.

Effects of berberine on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and a rat model of Parkinson's disease.

Kwon IH, Choi HS, Shin KS, Lee BK, Lee CK, Hwang BY, Lim SC, Lee MK.

Neurosci Lett. 2010 Dec 3;486(1):29-33. doi: 10.1016/j.neulet.2010.09.038. Epub 2010 Sep 17.

PMID:
20851167
16.

Neuroprotection by crocetin in a hemi-parkinsonian rat model.

Ahmad AS, Ansari MA, Ahmad M, Saleem S, Yousuf S, Hoda MN, Islam F.

Pharmacol Biochem Behav. 2005 Aug;81(4):805-13.

PMID:
16005057
17.

Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.

Costa G, Abin-Carriquiry JA, Dajas F.

Brain Res. 2001 Jan 12;888(2):336-342.

PMID:
11150495
18.

Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.

Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, Ishrat T, Chaturvedi RK, Agrawal AK, Islam F.

J Neurochem. 2005 Apr;93(1):94-104.

19.
20.

Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease.

Ariza D, Lima MM, Moreira CG, Dombrowski PA, Avila TV, Allemand A, Mendes DA, Da Cunha C, Vital MA.

Neurochem Res. 2010 Oct;35(10):1620-7. doi: 10.1007/s11064-010-0222-3. Epub 2010 Jun 26.

PMID:
20582568

Supplemental Content

Support Center